Toward clinically applicable biomarkers for asthma: An EAACI position paper
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000030" target="_blank" >RIV/00064190:_____/19:N0000030 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10409735
Result on the web
<a href="http://dx.doi.org/10.1111/all.13806" target="_blank" >http://dx.doi.org/10.1111/all.13806</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/all.13806" target="_blank" >10.1111/all.13806</a>
Alternative languages
Result language
angličtina
Original language name
Toward clinically applicable biomarkers for asthma: An EAACI position paper
Original language description
Inflammation, structural, and functional abnormalities within the airways are key features of asthma. Although these processes are well documented, their expression varies across the heterogeneous spectrum of asthma. Type 2 inflammatory responses are characterized by increased levels of eosinophils, FeNO, and type 2 cytokines in blood and/or airways. Presently, type 2 asthma is the best-defined endotype, typically found in patients with allergic asthma, but surprisingly also in nonallergic patients with (severe) asthma. The etiology of asthma with non-type 2 inflammation is less clear. During the past decade, targeted therapies, including biologicals and small molecules, have been increasingly integrated into treatment strategies of severe asthma. These treatments block specific inflammatory pathways or single mediators. Single or composite biomarkers help to identify patients who will benefit from these treatments. So far, only a few inflammatory biomarkers have been validated for clinical application. The European Academy of Allergy & Clinical Immunology Task Force on Biomarkers in Asthma was initiated to review different biomarker sampling methods and to investigate clinical applicability of new and existing inflammatory biomarkers (point-of-care) to support diagnosis, targeted treatment, and monitoring of severe asthma. Subsequently, we discuss existing and novel targeted therapies for asthma as well as applicable biomarkers.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30225 - Allergy
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ALLERGY
ISSN
0105-4538
e-ISSN
1398-9995
Volume of the periodical
74
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
17
Pages from-to
1835-1851
UT code for WoS article
000493013400002
EID of the result in the Scopus database
2-s2.0-85073573989